SWS Subsidiary Obtains Medical Device Registration Certificate for Single-Use Hemodialysis Blood Tubing Set

Regulation
โดย 财中社·Read original
Summary · why it matters

SWS wholly-owned subsidiary Chongqing Tianwaitian Biotechnology Co., Ltd. has obtained a medical device registration certificate from the National Medical Products Administration for a single-use hemodialysis blood tubing set. The certificate is valid from July 20, 2026 to July 19, 2031. The product is used to establish an extracorporeal circulation pathway during hemodialysis, hemofiltration, hemodiafiltration, and hemodialysis combined with hemoperfusion treatments. In the first quarter of 2026, SWS achieved revenue of 230 million yuan and a net profit attributable to the parent company of 54.48 million yuan.

Impact on stocks 1

Others▲ · 1 stocks

Off-coverage companies 1

重庆天外天生物技术有限公司Private▲ Positive
Regulationrelevance

Obtained medical device registration certificate for single-use hemodialysis blood tubing set from NMPA.

© 2026 MarketDXNews